Automate Your Wheel Strategy on ABBV
With Tiblio's Option Bot, you can configure your own wheel strategy including ABBV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABBV
- Rev/Share 33.6591
- Book/Share -1.4667
- PB -151.3309
- Debt/Equity -26.0193
- CurrentRatio 0.7245
- ROIC 0.0902
- MktCap 398773949400.0
- FreeCF/Share 11.6078
- PFCF 19.3871
- PE 167.4273
- Debt/Assets 0.5134
- DivYield 0.0295
- ROE 4.975
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ABBV | Wolfe Research | Outperform | Peer Perform | -- | -- | Jan. 8, 2026 |
| Resumed | ABBV | UBS | -- | Neutral | -- | $240 | Jan. 7, 2026 |
| Upgrade | ABBV | HSBC Securities | Hold | Buy | -- | $265 | Dec. 10, 2025 |
| Initiation | ABBV | Scotiabank | -- | Sector Outperform | -- | $280 | Nov. 13, 2025 |
| Downgrade | ABBV | DZ Bank | Buy | Hold | -- | $237 | Nov. 4, 2025 |
| Downgrade | ABBV | Erste Group | Buy | Hold | -- | -- | Oct. 14, 2025 |
| Downgrade | ABBV | HSBC Securities | Buy | Hold | -- | -- | Oct. 1, 2025 |
| Upgrade | ABBV | Berenberg | Hold | Buy | -- | $270 | Sept. 17, 2025 |
| Resumed | ABBV | Piper Sandler | -- | Overweight | -- | $231 | Aug. 12, 2025 |
| Upgrade | ABBV | Daiwa Securities | Neutral | Outperform | -- | $214 | Aug. 7, 2025 |
News
Final Trades: 3M, Abbvie, Salesforce and Intuitive Surgical
Published: April 22, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders
Published: April 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud.
Read More
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors – Contact Levi & Korsinsky
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.
Read More
The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ABBV
Published: April 21, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: April 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
One Sector Paying Big Dividends Is Off to the Best Start in 25 Years Despite Tariffs
Published: April 18, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.
Read More
After Tariff Flush, a Fresh Look at AbbVie Pharma (ABBV)
Published: April 15, 2025 by: See It Market
Sentiment: Positive
In my 2025 Outlook, I picked AbbVie Pharmaceuticals (NYSE: ABBV) as one to watch this year. Here is what I wrote: AbbVie (ABBV) AbbVie primarily works in immunology, oncology, neuroscience, eye care, and virology.
Read More
Trump Says Pharmaceutical Tariffs Coming in Near Future
Published: April 14, 2025 by: Bloomberg Markets and Finance
Sentiment: Negative
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
Read More
Trump says US pharma tariffs coming in not-too-distant future
Published: April 14, 2025 by: Reuters
Sentiment: Negative
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
Read More
ABBV vs. MRK: Which Drug Giant is a Better Buy Now?
Published: April 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Both ABBV and MRK are leading pharmaceutical companies with strong portfolios in oncology and immunology.
Read More
Final Trades: TJX, Meta, Abbvie and Taiwan Semi
Published: April 11, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV
Published: April 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 11, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cerevel-therapeutics-holdings-inc-lawsuit-submission-form?prid=142536&wire=1 or contact Joseph E. Levi, Esq.
Read More
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
Published: April 11, 2025 by: CNBC
Sentiment: Negative
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Read More
Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
The news of a likely import tariff hurt the share price of pharma giants like Novo Nordisk (NVO), Eli Lilly (LLY) and AstraZeneca (AZN), but Trump's announcement of a pause on reciprocal tariffs offsets the losses.
Read More
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Read More
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Published: April 09, 2025 by: WSJ
Sentiment: Negative
Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.
Read More
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squibb, Regeneron, Merck, Pfizer, Johnson & Johnson and Amgen, among others, all dropped on Wednesday.
Read More
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.
Read More
AbbVie Stock Rises 16% Year to Date: Time to Buy, Sell or Hold?
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
Read More
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Published: April 01, 2025 by: CNBC
Sentiment: Negative
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Read More
Bernstein's Courtney Breen: Merck, Novo Nordisk, others at high risk from tariffs
Published: April 01, 2025 by: CNBC Television
Sentiment: Negative
Courtney Breen, Bernstein senior analyst, joins CNBC's 'Money Movers' to discuss how to draw the line between tariff risks and company financials in pharmaceuticals, which companies are most at risk, and more.
Read More
Final Trades: PayPal, Meta, Abbvie and Snowflake
Published: March 28, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
5 Large Drug Stocks to Watch as Industry Recovers
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Industry Description
Read More
Only Have $500? 3 No-Brainer Stocks to Buy Right Now
Published: March 18, 2025 by: 24/7 Wall Street
Sentiment: Positive
Forget the old adage “it takes money to make money.
Read More
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Published: March 13, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Calls of the Day: United Airlines, Delta, IBM, Abbvie, Uber
Published: March 12, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
Siri & Glimstad Defeats AbbVie's Motion to Dismiss Illinois GIPA Lawsuit
Published: March 11, 2025 by: Accesswire
Sentiment: Neutral
Call to Action: Join Open Class Action Against AbbVie CHICAGO, IL / ACCESS Newswire / March 11, 2025 / Recently, the Northern District of Illinois denied AbbVie's motion to dismiss a lawsuit alleging that AbbVie violated the Illinois Genetic Information Privacy Act ("GIPA"). In Henry v.
Read More
AbbVie Inc. (ABBV) TD Cowen 45th Annual Health Care Conference (Transcript)
Published: March 05, 2025 by: Seeking Alpha
Sentiment: Neutral
AbbVie Inc. (NYSE:ABBV ) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET Company Participants Scott T. Reents - Executive Vice President and Chief Financial Officer Jeffrey R.
Read More
Here's How to Play AbbVie Stock as it Enters the Obesity Space
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
Read More
AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race
Published: March 03, 2025 by: Benzinga
Sentiment: Positive
On Monday, AbbVie Inc ABBV and Gubra A/S announced a license agreement to develop GUB014295, a long-acting amylin analog for obesity. GUB014295 is currently in a Phase 1 clinical trial.
Read More
About AbbVie Inc. (ABBV)
- IPO Date 2013-01-02
- Website https://www.abbvie.com
- Industry Drug Manufacturers - General
- CEO Robert A. Michael
- Employees 55000